Last reviewed · How we verify
Pertuzumab, trastuzumab-emtansine
Pertuzumab, trastuzumab-emtansine is a Small molecule drug developed by Fondazione del Piemonte per l'Oncologia. It is currently in Phase 2 development.
At a glance
| Generic name | Pertuzumab, trastuzumab-emtansine |
|---|---|
| Sponsor | Fondazione del Piemonte per l'Oncologia |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (PHASE2)
- A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America
- CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy (PHASE2)
- Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib (PHASE2)
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (PHASE2)
- De-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast Cancer (PHASE2)
- A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors (PHASE1, PHASE2)
- Diagnostic HER2DX-guided Treatment for Patients wIth Early-stage HER2-positive Breast Cancer (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pertuzumab, trastuzumab-emtansine CI brief — competitive landscape report
- Pertuzumab, trastuzumab-emtansine updates RSS · CI watch RSS
- Fondazione del Piemonte per l'Oncologia portfolio CI
Frequently asked questions about Pertuzumab, trastuzumab-emtansine
What is Pertuzumab, trastuzumab-emtansine?
Pertuzumab, trastuzumab-emtansine is a Small molecule drug developed by Fondazione del Piemonte per l'Oncologia.
Who makes Pertuzumab, trastuzumab-emtansine?
Pertuzumab, trastuzumab-emtansine is developed by Fondazione del Piemonte per l'Oncologia (see full Fondazione del Piemonte per l'Oncologia pipeline at /company/fondazione-del-piemonte-per-l-oncologia).
What development phase is Pertuzumab, trastuzumab-emtansine in?
Pertuzumab, trastuzumab-emtansine is in Phase 2.
Related
- Manufacturer: Fondazione del Piemonte per l'Oncologia — full pipeline